JP7489916B2 - Btnl8を発現するt細胞の検出 - Google Patents
Btnl8を発現するt細胞の検出 Download PDFInfo
- Publication number
- JP7489916B2 JP7489916B2 JP2020512006A JP2020512006A JP7489916B2 JP 7489916 B2 JP7489916 B2 JP 7489916B2 JP 2020512006 A JP2020512006 A JP 2020512006A JP 2020512006 A JP2020512006 A JP 2020512006A JP 7489916 B2 JP7489916 B2 JP 7489916B2
- Authority
- JP
- Japan
- Prior art keywords
- btnl8
- tregs
- cells
- garp
- lap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100025371 Butyrophilin-like protein 8 Human genes 0.000 title claims description 138
- 238000001514 detection method Methods 0.000 title claims description 57
- 210000001744 T-lymphocyte Anatomy 0.000 title claims description 49
- 101000934742 Homo sapiens Butyrophilin-like protein 8 Proteins 0.000 title claims description 26
- 210000003289 regulatory T cell Anatomy 0.000 claims description 113
- 238000000034 method Methods 0.000 claims description 77
- 210000004027 cell Anatomy 0.000 claims description 73
- 239000003550 marker Substances 0.000 claims description 58
- 101000716102 Homo sapiens T-cell surface glycoprotein CD4 Proteins 0.000 claims description 52
- 102100036011 T-cell surface glycoprotein CD4 Human genes 0.000 claims description 52
- 102100025946 Transforming growth factor beta activator LRRC32 Human genes 0.000 claims description 35
- 101710169732 Transforming growth factor beta activator LRRC32 Proteins 0.000 claims description 35
- 230000014509 gene expression Effects 0.000 claims description 30
- 238000011282 treatment Methods 0.000 claims description 27
- 101001043809 Homo sapiens Interleukin-7 receptor subunit alpha Proteins 0.000 claims description 25
- 102100021593 Interleukin-7 receptor subunit alpha Human genes 0.000 claims description 25
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims description 24
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims description 24
- 101001076422 Homo sapiens Interleukin-1 receptor type 2 Proteins 0.000 claims description 18
- 102100026017 Interleukin-1 receptor type 2 Human genes 0.000 claims description 18
- 101150111571 mreg gene Proteins 0.000 claims description 18
- 208000026278 immune system disease Diseases 0.000 claims description 17
- -1 CD121a Proteins 0.000 claims description 15
- 238000003757 reverse transcription PCR Methods 0.000 claims description 14
- 238000000684 flow cytometry Methods 0.000 claims description 11
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 10
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 10
- 210000004369 blood Anatomy 0.000 claims description 10
- 239000008280 blood Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 9
- 230000001105 regulatory effect Effects 0.000 claims description 9
- 238000012544 monitoring process Methods 0.000 claims description 8
- 239000013642 negative control Substances 0.000 claims description 8
- 208000023275 Autoimmune disease Diseases 0.000 claims description 5
- 210000002540 macrophage Anatomy 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 230000001939 inductive effect Effects 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 4
- 238000003753 real-time PCR Methods 0.000 claims description 4
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 claims description 3
- 206010020751 Hypersensitivity Diseases 0.000 claims description 3
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 claims description 3
- 230000000977 initiatory effect Effects 0.000 claims description 2
- 101710134031 CCAAT/enhancer-binding protein beta Proteins 0.000 claims 13
- 101710093674 Cyclic nucleotide-gated cation channel beta-1 Proteins 0.000 claims 13
- 101710199286 Cytosol aminopeptidase Proteins 0.000 claims 13
- 101710197780 E3 ubiquitin-protein ligase LAP Proteins 0.000 claims 13
- 101710204480 Lysosomal acid phosphatase Proteins 0.000 claims 13
- 101710089118 Probable cytosol aminopeptidase Proteins 0.000 claims 13
- 238000003881 globally optimized alternating phase rectangular pulse Methods 0.000 claims 13
- 102100023441 Centromere protein J Human genes 0.000 claims 10
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 6
- 101710140589 Butyrophilin-like protein 8 Proteins 0.000 description 114
- 239000000523 sample Substances 0.000 description 38
- 108090000623 proteins and genes Proteins 0.000 description 29
- 230000001506 immunosuppresive effect Effects 0.000 description 24
- 102400000401 Latency-associated peptide Human genes 0.000 description 23
- 101800001155 Latency-associated peptide Proteins 0.000 description 23
- 108020004999 messenger RNA Proteins 0.000 description 22
- 102000004169 proteins and genes Human genes 0.000 description 20
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 18
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- 239000013615 primer Substances 0.000 description 13
- 210000000056 organ Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 239000012634 fragment Substances 0.000 description 9
- 101150041092 BTNL8 gene Proteins 0.000 description 8
- 230000000735 allogeneic effect Effects 0.000 description 8
- 210000003162 effector t lymphocyte Anatomy 0.000 description 8
- 238000002493 microarray Methods 0.000 description 8
- 239000002773 nucleotide Substances 0.000 description 8
- 125000003729 nucleotide group Chemical group 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- 230000001363 autoimmune Effects 0.000 description 7
- 230000027455 binding Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000011002 quantification Methods 0.000 description 7
- 239000003155 DNA primer Substances 0.000 description 6
- 108091034117 Oligonucleotide Proteins 0.000 description 6
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 210000002602 induced regulatory T cell Anatomy 0.000 description 6
- 230000003834 intracellular effect Effects 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 230000002103 transcriptional effect Effects 0.000 description 6
- 238000001262 western blot Methods 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 5
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 5
- 238000002054 transplantation Methods 0.000 description 5
- 102100027581 Forkhead box protein P3 Human genes 0.000 description 4
- 101000861452 Homo sapiens Forkhead box protein P3 Proteins 0.000 description 4
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 4
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 4
- 108010038453 Interleukin-2 Receptors Proteins 0.000 description 4
- 102000010789 Interleukin-2 Receptors Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 206010047115 Vasculitis Diseases 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 239000011324 bead Substances 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 239000002987 primer (paints) Substances 0.000 description 4
- 238000010839 reverse transcription Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 238000011895 specific detection Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010038498 Interleukin-7 Receptors Proteins 0.000 description 3
- 102000010782 Interleukin-7 Receptors Human genes 0.000 description 3
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 230000006037 cell lysis Effects 0.000 description 3
- 208000037976 chronic inflammation Diseases 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 3
- 230000028993 immune response Effects 0.000 description 3
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 3
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 210000005259 peripheral blood Anatomy 0.000 description 3
- 239000011886 peripheral blood Substances 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- QCPFFGGFHNZBEP-UHFFFAOYSA-N 4,5,6,7-tetrachloro-3',6'-dihydroxyspiro[2-benzofuran-3,9'-xanthene]-1-one Chemical compound O1C(=O)C(C(=C(Cl)C(Cl)=C2Cl)Cl)=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 QCPFFGGFHNZBEP-UHFFFAOYSA-N 0.000 description 2
- RYVNIFSIEDRLSJ-UHFFFAOYSA-N 5-(hydroxymethyl)cytosine Chemical compound NC=1NC(=O)N=CC=1CO RYVNIFSIEDRLSJ-UHFFFAOYSA-N 0.000 description 2
- 108091093088 Amplicon Proteins 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 102000000844 Cell Surface Receptors Human genes 0.000 description 2
- 108010001857 Cell Surface Receptors Proteins 0.000 description 2
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100034343 Integrase Human genes 0.000 description 2
- 108010066719 Interleukin Receptor Common gamma Subunit Proteins 0.000 description 2
- 102000018682 Interleukin Receptor Common gamma Subunit Human genes 0.000 description 2
- 102000008121 Latent TGF-beta Binding Proteins Human genes 0.000 description 2
- 108010049807 Latent TGF-beta Binding Proteins Proteins 0.000 description 2
- 208000004302 Microvascular Angina Diseases 0.000 description 2
- 208000026018 Microvascular coronary artery disease Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 206010034576 Peripheral ischaemia Diseases 0.000 description 2
- 108091034057 RNA (poly(A)) Proteins 0.000 description 2
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 108020004566 Transfer RNA Proteins 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000003491 array Methods 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000000139 costimulatory effect Effects 0.000 description 2
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000006058 immune tolerance Effects 0.000 description 2
- 239000003018 immunosuppressive agent Substances 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 201000006417 multiple sclerosis Diseases 0.000 description 2
- 210000000066 myeloid cell Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000002105 nanoparticle Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 108020004418 ribosomal RNA Proteins 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000002198 surface plasmon resonance spectroscopy Methods 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 2
- WGTODYJZXSJIAG-UHFFFAOYSA-N tetramethylrhodamine chloride Chemical group [Cl-].C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C(O)=O WGTODYJZXSJIAG-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- LOGFVTREOLYCPF-KXNHARMFSA-N (2s,3r)-2-[[(2r)-1-[(2s)-2,6-diaminohexanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoic acid Chemical compound C[C@@H](O)[C@@H](C(O)=O)NC(=O)[C@H]1CCCN1C(=O)[C@@H](N)CCCCN LOGFVTREOLYCPF-KXNHARMFSA-N 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 208000030090 Acute Disease Diseases 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 208000031104 Arterial Occlusive disease Diseases 0.000 description 1
- 206010003827 Autoimmune hepatitis Diseases 0.000 description 1
- 102000005738 B7 Antigens Human genes 0.000 description 1
- 108010045634 B7 Antigens Proteins 0.000 description 1
- 208000009137 Behcet syndrome Diseases 0.000 description 1
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 description 1
- 208000033222 Biliary cirrhosis primary Diseases 0.000 description 1
- 208000033386 Buerger disease Diseases 0.000 description 1
- 102000004555 Butyrophilins Human genes 0.000 description 1
- 108010017533 Butyrophilins Proteins 0.000 description 1
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 208000031994 Cutaneous small vessel vasculitis Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010013700 Drug hypersensitivity Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 208000027761 Hepatic autoimmune disease Diseases 0.000 description 1
- 101000917858 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 101000917839 Homo sapiens Low affinity immunoglobulin gamma Fc region receptor III-B Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101150029684 IL2RA gene Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010057368 Interleukin-1 Type I Receptors Proteins 0.000 description 1
- 108010008144 Interleukin-1 Type II Receptors Proteins 0.000 description 1
- 102000003777 Interleukin-1 beta Human genes 0.000 description 1
- 108090000193 Interleukin-1 beta Proteins 0.000 description 1
- 102100026016 Interleukin-1 receptor type 1 Human genes 0.000 description 1
- 102000010920 Interleukin-1 receptor type II Human genes 0.000 description 1
- 102000003812 Interleukin-15 Human genes 0.000 description 1
- 108090000172 Interleukin-15 Proteins 0.000 description 1
- 102000004125 Interleukin-1alpha Human genes 0.000 description 1
- 108010082786 Interleukin-1alpha Proteins 0.000 description 1
- 102000004388 Interleukin-4 Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000585 Interleukin-9 Human genes 0.000 description 1
- 108010002335 Interleukin-9 Proteins 0.000 description 1
- 208000003456 Juvenile Arthritis Diseases 0.000 description 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 description 1
- 208000011200 Kawasaki disease Diseases 0.000 description 1
- 102100029185 Low affinity immunoglobulin gamma Fc region receptor III-B Human genes 0.000 description 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 238000000636 Northern blotting Methods 0.000 description 1
- 108020004711 Nucleic Acid Probes Proteins 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 208000031481 Pathologic Constriction Diseases 0.000 description 1
- 206010034277 Pemphigoid Diseases 0.000 description 1
- 201000011152 Pemphigus Diseases 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010010677 Phosphodiesterase I Proteins 0.000 description 1
- 208000012654 Primary biliary cholangitis Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 206010038470 Renal infarct Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 206010039710 Scleroderma Diseases 0.000 description 1
- 239000012507 Sephadex™ Substances 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 208000021386 Sjogren Syndrome Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 230000006052 T cell proliferation Effects 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 206010043561 Thrombocytopenic purpura Diseases 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023935 Transmembrane glycoprotein NMB Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 206010047112 Vasculitides Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000004504 adult stem cell Anatomy 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009134 cell regulation Effects 0.000 description 1
- 239000002458 cell surface marker Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000019069 chronic childhood arthritis Diseases 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000006020 chronic inflammation Effects 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229940104302 cytosine Drugs 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002074 deregulated effect Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000003979 eosinophil Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000011223 gene expression profiling Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 208000008384 ileus Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008629 immune suppression Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 238000012151 immunohistochemical method Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 229940124589 immunosuppressive drug Drugs 0.000 description 1
- 238000002650 immunosuppressive therapy Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000007641 inkjet printing Methods 0.000 description 1
- 229940100994 interleukin-7 Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 210000004153 islets of langerhan Anatomy 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000004901 leucine-rich repeat Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 208000008585 mastocytosis Diseases 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000003071 memory t lymphocyte Anatomy 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 238000013188 needle biopsy Methods 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002853 nucleic acid probe Substances 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000004248 oligodendroglia Anatomy 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 201000001976 pemphigus vulgaris Diseases 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 150000008300 phosphoramidites Chemical class 0.000 description 1
- 238000000206 photolithography Methods 0.000 description 1
- 230000006584 pituitary dysfunction Effects 0.000 description 1
- 230000010287 polarization Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 208000005987 polymyositis Diseases 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000011533 pre-incubation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 235000019833 protease Nutrition 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000010833 quantitative mass spectrometry Methods 0.000 description 1
- 108700015048 receptor decoy activity proteins Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000002702 ribosome display Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 238000001542 size-exclusion chromatography Methods 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 208000037804 stenosis Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000006016 thyroid dysfunction Effects 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 108091007466 transmembrane glycoproteins Proteins 0.000 description 1
- 102000035160 transmembrane proteins Human genes 0.000 description 1
- 108091005703 transmembrane proteins Proteins 0.000 description 1
- 238000000539 two dimensional gel electrophoresis Methods 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
- G01N33/56972—White blood cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4614—Monocytes; Macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46434—Antigens related to induction of tolerance to non-self
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Cell Biology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Hematology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Virology (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Developmental Biology & Embryology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
(a)Tregと関連することが知られている少なくとも1つのマーカー;
(b)マーカーBTNL8
を検出することを含む。
(a)CD4、GARPおよびBTNL8、
(b)CD4、LAPおよびBTNL8、
(c)CD4、GARP、LAPおよびBTNL8、
(d)CD4、CD25、GARPおよびBTNL8、
(e)CD4、CD25、LAPおよびBTNL8、
(f)CD4、CD25、GARP、LAPおよびBTNL8、
(g)CD4、CD127、GARPおよびBTNL8、
(h)CD4、CD127、LAPおよびBTNL8、
(i)CD4、CD127、GARP、LAPおよびBTNL8、
(j)CD4、CD121a、GARPおよびBTNL8、
(k)CD4、CD121a、LAPおよびBTNL8、
(l)CD4、CD121a、GARP、LAPおよびBTNL8、
(m)CD4、CD121b、GARPおよびBTNL8、
(n)CD4、CD121b、LAPおよびBTNL8、
(o)CD4、CD121b、GARP、LAPおよびBTNL8。
(a)前記の免疫疾患または症状の処置が開始された後に対象から得られた試料を提供し;
(b)上記の検出方法を行い;
(c)BTNL8発現Tregを定量すること;
を含み、処置開始後のBTNL8発現Treg数の増加は処置が有効であることを示す。
(a)Tregを含有する、または含有すると思われる試料を提供し;
(b)BTNL8およびTregと関連することが知られている少なくとも1つのマーカーの発現により、試料中に含有される他の細胞からTregを分離することを含み、該マーカーは好ましくはCD25、CD127、CD121a、CD121b、GARP、LAPおよびFoxP3の群から選択される。
(a)Tregと関連することが知られている少なくとも1つのマーカー、好ましくはCD25、CD127、CD121a、CD121b、GARP、LAPまたはFoxP3の検出のための手段;および
(b)BTNL8の検出のための手段。
[1] Hutchinson & Geissler (2015), Kidney Int.
[2] Ferrer et al. (2014), Immunol. Rev. 258, 102-116.
[3] Trzonkowski et al. (2015), Sci. Transl. Med. 7, 304psl8.
[4] Thomson et al (2016), Front Immunol. 7, 15.
[5] Geissler & Hutchinson (2013), Curr. Opin. Organ Transplant. 18, 408-415.
[6] Riquelme et al. (2012), Transplantation Research 1(1): 17
[7] Hutchinson at al. (2011), J. Immunol. 187, 2072-2078
[8] Riquelme et al. (2013), Mol Ther. 2013, 21(2): 409-22
[9] Broichhausen et al. (2012), Curr. Opin. Organ Transplant. 17, 332-342.
[10] Hutchinson et al. (2011), Methods Mol. Biol. 677, 181-192.
[11] Hutchinson et al. (2010), Transplantation 90, 184.
[12] Hutchinson at al. (2011), J. Immunol. 187, 2072-2078.
[13] Riquelme et al. (2013), Mol. Ther. 21, 409-422.
[14] Listen et al. (2013), Adv Immunol, 1 19:85-106
[15] Battaglia & Roncarolo (2009), Eur J Immunol., 39(12): 3296-300.
[16] Abeler-Dorner et al. (2012), Trends Immunol. 33, 34-41.
[17] Chapoval et al. (2013). Mol. Immunol. 56, 819-828.
[18] Leonard et al. (1985), Science. 228 (4707): 1547-9.
[19] Noguchi et al (1993), Science. 262 (5141): 1877-80.
[20] Kroemer & Richards (1996), Protein Eng. 9 (12): 1135-42.
[21] Ollendorff et al. (1992), Mamm Genome 2: 195-200.
[22] Ollendorff et al. (1994), Cell Growth Differ 5:213-219.
[23] Ochi et al. (2006), Nat. Med. 12, 627-635.
[24] Chen et al. (2009), Eur. J. Immunol. 39, 3423-3435.
[25] Liu et al. (2015), PLoS One, 10(6): e0131086.
[26] Garlanda et al. (2013), Immunity 39: 1003-1018.
Claims (13)
- 対象において制御性T細胞(Treg)を検出するための方法であって、該対象から得られた試料において:
(a)Tregと関連することが知られている少なくとも1つのマーカーであって、CD25、CD127、CD121a、CD121b、GARP、LAPおよびFoxP3の群から選択されるマーカー、及び
(b)BTNL8
を検出することを含む、方法。 - 次のマーカー:CD3、CD4、TIGITおよびHELIOSのうち1つ以上の検出をさらに含む、請求項1に記載の方法。
- 以下の(a)~(о):
(a)CD4、GARPおよびBTNL8の組み合わせ、
(b)CD4、LAPおよびBTNL8の組み合わせ、
(c)CD4、GARP、LAPおよびBTNL8の組み合わせ、
(d)CD4、CD25、GARPおよびBTNL8の組み合わせ、
(e)CD4、CD25、LAPおよびBTNL8の組み合わせ、
(f)CD4、CD25、GARP、LAPおよびBTNL8の組み合わせ、
(g)CD4、CD127、GARPおよびBTNL8の組み合わせ、
(h)CD4、CD127、LAPおよびBTNL8の組み合わせ、
(i)CD4、CD127、GARP、LAPおよびBTNL8の組み合わせ、
(j)CD4、CD121a、GARPおよびBTNL8の組み合わせ、
(k)CD4、CD121a、LAPおよびBTNL8の組み合わせ、
(l)CD4、CD121a、GARP、LAPおよびBTNL8の組み合わせ、
(m)CD4、CD121b、GARPおよびBTNL8の組み合わせ、
(n)CD4、CD121b、LAPおよびBTNL8の組み合わせ、並びに
(o)CD4、CD121b、GARP、LAPおよびBTNL8の組み合わせ
のいずれか1つの組み合わせの検出を含む、請求項1又は2に記載の方法。 - 該Tregが定量されるステップをさらに含む、請求項1~3の何れかに記載の方法。
- 前記試料が、前記Tregを検出する前に、制御性マクロファージ(Mreg)を含んだ細胞ベースプロダクトが投与された対象に由来する、請求項1~4の何れかに記載の方法。
- 前記Tregと関連することが知られている少なくとも1つのマーカーおよび前記BTNL8の検出が、以下の技術:フローサイトメトリー、PCR、RT-PCR、リアルタイムPCRおよびELISAのうち1つ以上を使用する、請求項1~5の何れかに記載の方法。
- 前記試料が血液試料または血液由来試料である、請求項1~6の何れかに記載の方法。
- 非Tregが陰性対照として使用される、請求項1~6の何れかに記載の方法。
- 対象における免疫学的疾患または症状の処置をモニタリングまたは評価するための方法であって、
(a)前記免疫学的疾患または症状の処置が開始された後に前記対象から得られた試料を提供し、前記免疫学的疾患または症状が、移植片拒絶、自己免疫疾患、炎症疾患および過敏症反応からなる群より選択され、前記処置が、Tregの投与若しくはTregを誘導可能な制御性マクロファージ(Mreg)の投与を含み;
(b)請求項1~8に記載の方法を実行し;
(c)BTNL8発現Tregを定量すること
を含み;
処置開始後のBTNL8発現Tregの数の増加が、該処置が有効であることを示す、
方法。 - 制御性T細胞(Treg)を単離する方法であって、
(a)Tregを含有するまたは含有すると思われる試料を提供し;
(b)BTNL8およびTregと関連することが知られている少なくとも1つのマーカーの発現により、該試料中に含有される他の細胞からTregを分離することを含み、前記マーカーが、CD25、CD127、CD121a、CD121b、GARP、LAPおよびFoxP3の群から選択される、
方法。 - Tregを検出、濃縮、単離および/または定量するための、BTNL8タンパク質に特異的な親和性を有する化合物の使用。
- 前記化合物が、BTNL8に対する抗体または抗体断片である、請求項11に記載の使用。
- T細胞のプール中で制御性T細胞(Treg)を検出するための方法であって、対象から得られた試料において:
(a)Tregと関連することが知られている少なくとも1つのマーカーであって、CD25、CD127、CD121a、CD121b、GARP、LAP及びFoxP3の群より選択されるマーカー、及び
(b)BTNL8
を検出することを含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17188204.6 | 2017-08-28 | ||
EP17188204.6A EP3450981A1 (en) | 2017-08-28 | 2017-08-28 | Btnl8 as a marker for tregs |
PCT/EP2018/073124 WO2019042996A1 (en) | 2017-08-28 | 2018-08-28 | DETECTION OF LYMPHOCYTES T EXPRESSING BTNL8 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2020531853A JP2020531853A (ja) | 2020-11-05 |
JP7489916B2 true JP7489916B2 (ja) | 2024-05-24 |
Family
ID=59738229
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2020512006A Active JP7489916B2 (ja) | 2017-08-28 | 2018-08-28 | Btnl8を発現するt細胞の検出 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20200256871A1 (ja) |
EP (2) | EP3450981A1 (ja) |
JP (1) | JP7489916B2 (ja) |
CA (1) | CA3074052A1 (ja) |
WO (1) | WO2019042996A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111971052A (zh) | 2018-02-08 | 2020-11-20 | 小利兰.斯坦福大学托管委员会 | 用于异基因造血干细胞移植的方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279834A1 (en) | 2005-03-31 | 2008-11-13 | Case Western Reserve University | Methods and Reagents for Identifying/Isolating T Regulatory (Treg) Cells and for Treating Individuals |
US20090142308A1 (en) | 2006-04-25 | 2009-06-04 | Joslin Diabetes Center, Inc. | Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells |
JP2013501057A (ja) | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性t細胞のinvivoにおける増殖 |
JP2016222708A (ja) | 2010-04-16 | 2016-12-28 | メドヴェット・サイエンス・ピーティーワイ・リミテッド | Pi16に結合するタンパク質とその利用 |
WO2017025533A1 (en) | 2015-08-11 | 2017-02-16 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | In-vitro methods for the detection of autoimmune diseases or conditions |
JP2019508067A (ja) | 2016-03-11 | 2019-03-28 | トリゼル ゲーエムベーハー | 新しい免疫調節細胞およびその製造方法 |
WO2019110370A1 (en) | 2017-12-07 | 2019-06-13 | Universität Regensburg | New drug screening assay using regulatory macrophages |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2563955T3 (es) * | 2005-08-02 | 2016-03-16 | Centenary Institute Of Cancer Medicine & Cell Biology | Método para identificar linfocitos T reguladores |
WO2010022341A1 (en) * | 2008-08-21 | 2010-02-25 | The United State Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of enriching and using regulatory t cells |
EP2597463A1 (en) * | 2011-11-22 | 2013-05-29 | Medizinische Hochschule Hannover | Methods of enrichment and isolation of regulatory T-cells and use of the same |
JP6574179B2 (ja) * | 2013-07-31 | 2019-09-11 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | エフェクターtレグ細胞を同定するための方法及びキット |
-
2017
- 2017-08-28 EP EP17188204.6A patent/EP3450981A1/en not_active Ceased
-
2018
- 2018-08-28 EP EP18756469.5A patent/EP3676614A1/en active Pending
- 2018-08-28 WO PCT/EP2018/073124 patent/WO2019042996A1/en unknown
- 2018-08-28 US US16/643,252 patent/US20200256871A1/en active Pending
- 2018-08-28 CA CA3074052A patent/CA3074052A1/en active Pending
- 2018-08-28 JP JP2020512006A patent/JP7489916B2/ja active Active
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080279834A1 (en) | 2005-03-31 | 2008-11-13 | Case Western Reserve University | Methods and Reagents for Identifying/Isolating T Regulatory (Treg) Cells and for Treating Individuals |
US20090142308A1 (en) | 2006-04-25 | 2009-06-04 | Joslin Diabetes Center, Inc. | Methods for treating autoimmune disease by inducing autoantigen-specific regulatory CD4+ T cells |
JP2013501057A (ja) | 2009-08-03 | 2013-01-10 | ユニバーシティー・オブ・マイアミ | 制御性t細胞のinvivoにおける増殖 |
JP2016222708A (ja) | 2010-04-16 | 2016-12-28 | メドヴェット・サイエンス・ピーティーワイ・リミテッド | Pi16に結合するタンパク質とその利用 |
WO2017025533A1 (en) | 2015-08-11 | 2017-02-16 | Universitätsmedizin Der Johannes Gutenberg-Universität Mainz | In-vitro methods for the detection of autoimmune diseases or conditions |
JP2019508067A (ja) | 2016-03-11 | 2019-03-28 | トリゼル ゲーエムベーハー | 新しい免疫調節細胞およびその製造方法 |
WO2019110370A1 (en) | 2017-12-07 | 2019-06-13 | Universität Regensburg | New drug screening assay using regulatory macrophages |
Non-Patent Citations (4)
Title |
---|
L. Walter,Generation of BTNL8+ Inducible Tregs By Allogeneic Human Regulatory Macrophages Is IDO- and B7-Dependent,Transplantation,2014年07月15日,Vol.98,Page.396 |
Paloma Riquelme,Novel molecules mediate specialized functions of human regulatory macrophages,Curr Opin Organ Transplant,2018年,Vol.23,Page.533-537 |
Paloma Riquelme,TIGIT+ iTregs elicited by human regulatory macrophages control T cell immunity,NATURE COMMUNICATIONS,2018年07月20日,Vol.9 No.1,Page.2858 |
Ryan M. Swanson,Butyrophilin-like 2 Modulates B7 Costimulation To Induce Foxp3 Expression and Regulatory T Cell Development in Mature T Cells,The Journal of Immunology,2013年03月01日,Vol.190 No.5,Page.2027-2035 |
Also Published As
Publication number | Publication date |
---|---|
EP3450981A1 (en) | 2019-03-06 |
WO2019042996A1 (en) | 2019-03-07 |
US20200256871A1 (en) | 2020-08-13 |
CN111316104A (zh) | 2020-06-19 |
EP3676614A1 (en) | 2020-07-08 |
JP2020531853A (ja) | 2020-11-05 |
CA3074052A1 (en) | 2019-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Piera-Velazquez et al. | Endothelial to mesenchymal transition: role in physiology and in the pathogenesis of human diseases | |
Della-Torre et al. | B lymphocytes directly contribute to tissue fibrosis in patients with IgG4-related disease | |
Page et al. | Expression of the DNA-binding factor TOX promotes the encephalitogenic potential of microbe-induced autoreactive CD8+ T cells | |
Yang et al. | Impaired function of regulatory T cells in patients with psoriasis is mediated by phosphorylation of STAT3 | |
Cherrier et al. | Notch, Id2, and RORγt sequentially orchestrate the fetal development of lymphoid tissue inducer cells | |
KR102197524B1 (ko) | 특발성 폐 섬유증의 예후, 진단 및 치료 방법 | |
Nakamura et al. | Isolation and expression profiling of genes upregulated in bone marrow-derived mononuclear cells of rheumatoid arthritis patients | |
Li et al. | miR‐10a restores human mesenchymal stem cell differentiation by repressing KLF4 | |
AU2011325871B2 (en) | Markers of endothelial progenitor cells and uses thereof | |
Xie et al. | Semaphorin 4D induces an imbalance of Th17/Treg cells by activating the aryl hydrocarbon receptor in ankylosing spondylitis | |
Schoenmaker et al. | The effect of Activin‐A on periodontal ligament fibroblasts‐mediated osteoclast formation in healthy donors and in patients with fibrodysplasia ossificans progressiva | |
Higgins et al. | DNA oligonucleotide microarray technology identifies fisp-12 among other potential fibrogenic genes following murine unilateral ureteral obstruction (UUO): modulation during epithelial-mesenchymal transition | |
Talker et al. | Monocyte biology conserved across species: Functional insights from cattle | |
Blanco et al. | Genome‐Wide Transcriptional and Functional Analysis of Endoglin Isoforms in the Human Promonocytic Cell Line U937 | |
Li et al. | Helios expression in regulatory T cells promotes immunosuppression, angiogenesis and the growth of leukemia cells in pediatric acute lymphoblastic leukemia | |
JP7489916B2 (ja) | Btnl8を発現するt細胞の検出 | |
Wang et al. | E3-ligase Skp2 regulates β-catenin expression and maintains hematopoietic stem cell homing | |
US20220348870A1 (en) | Materials and methods for modifying the activity of t cells | |
CN111316104B (zh) | 表达btnl8的t-细胞的检测 | |
Hu et al. | Differential gene expression in oligodendrocyte progenitor cells, oligodendrocytes and type II astrocytes | |
Pérez et al. | Expression of Fas, FasL, and soluble Fas mRNA in endomyocardial biopsies of human cardiac allografts | |
US9678062B2 (en) | Methods and compositions for expanding cells and improving engraftment | |
Schwartz et al. | Transcriptional and functional consequences of Oncostatin M signaling on young Dnmt3a-mutant hematopoietic stem cells | |
JP2006349658A (ja) | 神経系癌幹細胞の検出試薬、神経系癌幹細胞を分離する方法、神経系癌幹細胞、及び神経芽腫の予後診断薬。 | |
US20180321223A1 (en) | Method for Monitoring the Immunological Profile of a Subject |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20210811 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20220620 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220628 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20220927 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20221128 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20221226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230322 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230619 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230814 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230921 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20231107 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240205 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20240416 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240514 |